Introduction
============

Invasive cervical cancer (ICC) remains a leading cause of death among women in low-resource settings \[[@B1]\] and virtually every case of ICC is caused by HPV \[[@B2]\]. Genital HPV infection is predominantly, but not exclusively, a sexually transmitted infection and about 50% to 80% sexually active women are infected by this virus at least once in their lifetime \[[@B3],[@B4]\]. Worldwide, women in developing countries account for about 85% of both annual cases of ICC estimated at 493,000 and annual deaths from ICC estimated at 273,500 \[[@B1]\]. Men play an important role in HPV transmission as HPV DNA has been detected in the genitalia of up to 73% of healthy men \[[@B5]\].

Over 100 HPV genotypes have been identified and are divided into high-risk (HR) and low risk (LR) depending on their potential to cause cancer. There are about 15 cancer causing HPV genotypes that are responsible for 5% of all human cancers but predominantly cervical cancer and other anogenital cancers \[[@B6]\]. HPV 16 and HPV 18 are the most virulent HR-HPV genotypes causing about 70% of all ICC in the world \[[@B7]\]. Two preventive vaccines targeting HPV 16 and 18 have been developed and are currently licensed in over 100 countries including Uganda; Cervarix^®^, a bivalent HPV 16/18 from GlaxoSmithKline Biologicals (GSK) and Gardasil^®^, a quadrivalent HPV 6/11/16/18 vaccine from MSD Merck. Gardasil also targets two LR-HPV genotypes 6 and 11, which together cause 90% of genital warts \[[@B8]\]. These current preventive HPV vaccines however, offer protection only against a few cancer causing HPV genotypes.

Uganda has a large burden of ICC. Current estimates indicate that every year, 3,577 women are diagnosed with ICC and 2,464 die from the disease. Compared to the USA, the age adjusted cervical cancer incidence per 100,000 population per year is 8.3 times higher in Uganda (47.5 vs.5.7) and age adjusted death rate as a result of ICC is 20.5 times higher (34.9 vs. 1.7) \[[@B9]\]. The high incidence of ICC is a reflection of prevalent HR-HPV infections and failure to prevent their clinical manifestations by effective screening programs that have dramatically reduced incidence in developed countries \[[@B10]\]. The introduction of Cervarix^®^by the Program for Appropriate Technology for Health (PATH) in partnership with the Uganda Ministry of Health may offer the greatest hope of significant reduction of ICC burden provided the vaccine is widely and properly delivered \[[@B11]\]. Furthermore, harmonizing primary (vaccination) and secondary prevention (screening) will result in greater reduction of ICC than either program alone \[[@B12]\].

Limited data are however, available on the distribution of HPV genotypes in the general population and in ICC in Uganda. Yet, with the advent of HPV vaccination, such information is crucial for policy makers to predict how HPV vaccination and HPV-based screening will influence prevention of ICC. Moreover, even with a successful vaccination program, vaccinated women will still require screening to detect those that will develop ICC from other HR-HPV genotypes that are not prevented by current vaccines. Therefore, the objective of this review was to summarize published data on HPV infection in Uganda. This review will provide useful baseline information for evaluating the impact of preventive HPV vaccines and HPV based technologies used in screening programs.

Methods
=======

PubMed/MEDLINE and HINARI websites were searched for peer reviewed English language published medical literature on HPV infection in Uganda up to November 30, 2010. The search was conducted using the following medical subject heading (MESH) and text words either singly or in combination: \"HPV\", \"genotypes\",\" cervical cancer\", \"screening\", \"vaccination\", \"serology\" and \"Uganda\". Eligible studies were selected according to the following criteria: DNA-confirmed cervical or male genital HPV prevalence, HPV incidence estimates and HPV seroprevalence among participants. From each article, information on first author, publication journal and date, dates of sample collection, HPV detection methods, study design, anatomical site and methods of sample collection, population description, mean or median age of sample with range when available, sample size, the prevalence of HIV when available, the prevalence of HPV (overall, high risk, low risk, specific genotypes) as well as the prevalence of HPV among HIV positive and HIV negative women. Risk factors for HPV infection were also extracted when available.

Twenty studies were found and were included in the review: 9 prevalence studies, 2 prospective cohort studies in women, 3 randomized controlled trials in men, 4 studies on ICC, and 2 seroprevalence studies.

Methods used for the detection of HPV DNA, typing for specific genotypes and to determine seroprevalence
--------------------------------------------------------------------------------------------------------

Various techniques and assays were used for detection of HPV DNA and genotyping. Polymerase Chain Reaction™ (PCR) using generic or consensus primers and Hybrid capture™ 2 (HC2, Digene Co., Gaithersburg, MD, USA) were used in majority of studies. Both techniques have been optimized to detect 13 HR-HPV genotypes \[[@B13]\]. However, some studies used the Southern Blot technique which generally has low sensitivity and detects only a few HR-HPV genotypes. One HPV seroprevalence study was done before the World Health Organization (WHO) developed international standard reagents for calibration of HPV DNA assays and kits \[[@B14]\]. Therefore, caution should be taken when interpreting results from the different studies as the sensitivities and specificities of the HPV assays vary widely depending on the type and quality of the biological specimen and the type and quality of reagents used. Additionally, assays differ in their ability to detect different HPV genotypes particularly where there are co-infections with multiple HPV types \[[@B15]\].

Results
=======

The findings from studies conducted in selected populations across the country are summarized in Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}, [4](#T4){ref-type="table"}, [5](#T5){ref-type="table"}, [6](#T6){ref-type="table"}.

###### 

HPV prevalence and genotype distribution in women with and without cervical abnormalities

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                              Area, subjects                                                                                                                                Study design                                  HPV test                                                   HPV prevalence for any, HR\*, LR\*\* and specific genotypes among all tested women^a^or only HPV positive women^b^   HPV prevalence and type specific genotypes among among all tested women^a^or only HPV positive women^b^by HIV status   Comments
  ----------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- ---------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- -----------------------------------------
  **Population-Based studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Serwadda et al., 1999 \[[@B52]\]    Rakai district, Random sample of 960 women aged 15-59 years using self collected vaginal swabs                                                Cross-sectional                               Hybrid Capture 2                                           Any HR-HPV^a^, 16.7%                                                                                                 *HIV status^a^*\                                                                                                       HIV prevalence^a^, 17.8%
                                                                                                                                                                                                                                                                                                                                                                                                                  HIV+, 44.3%\                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                  HIV-, 10.2%                                                                                                            

  Safaeian et al., 2007 \[[@B53]\]    Rakai district, 606 women, median age 30 years (25-38 years)                                                                                  Baseline of a population-based cohort study   Hybrid Capture 2/PGMY 09/11 assay                          Any HR-HPV^a^, 19%\                                                                                                  *HIV status^a^*\                                                                                                       HIV prevalence^a^, 15.7%
                                                                                                                                                                                                                                                                                             *Type-specific genotypes^a^*\                                                                                        *HIV positive*\                                                                                                        
                                                                                                                                                                                                                                                                                             HPV 16, 4.5%\                                                                                                        Self-collected, 40%\                                                                                                   
                                                                                                                                                                                                                                                                                             HPV 52, 4.4%\                                                                                                        Physician collected, 37%\                                                                                              
                                                                                                                                                                                                                                                                                             HPV 66, 3.0%\                                                                                                        *HIV negative*\                                                                                                        
                                                                                                                                                                                                                                                                                             HPV 58, 3.0%                                                                                                         Self-collected, 15%\                                                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                  Physician collected, 16%                                                                                               

  Asiimwe et al., 2008 \[[@B21]\]     Bushenyi district, 314 women with median age of 27 years (range,18-49) using self collected vaginal swabs                                     Cross-sectional                               Hybrid Capture 2 assay                                     Any HR-HPV^a^, 17.2%                                                                                                                                                                                                                        HIV prevalence^a^, 5.6% (self-reported)

  Safaeian et al., 2008b \[[@B20]\]   Rakai district, 926 sexually exprienced women aged 15-49 years, mean age 26 years, who provided at least 3 consecutive self-collected swabs   Population-based cross-sectional study        Hybrid Capture 2/Prototype Roche reverse line blot assay   Any HR-HPV^a^, 19.2%\                                                                                                *HIV status^a^*\                                                                                                       HIV prevalence^a^, 13.7%
                                                                                                                                                                                                                                                                                             *Type-specific genotypes^a^*\                                                                                        HIV+, 46.6%\                                                                                                           
                                                                                                                                                                                                                                                                                             HPV 52, 2.2%\                                                                                                        HIV-, 14.8%                                                                                                            
                                                                                                                                                                                                                                                                                             HPV 16, 2.1%\                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                             HPV 51, 1.7%\                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                             HPV 66, 1.5%\                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                             HPV 68, 1.3%                                                                                                                                                                                                                                

  **Clinic-Based Studies**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  *Adult women*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Blossom et al., 2007 \[[@B17]\]     STI clinic in Kampala, 106 women mean age 26.3 years (range,18-51)                                                                            Cross-sectional                               Roche PCR/reverse strip assay                              Any HPV^a^, 46.2%\                                                                                                   *Any HPV type^a^*\                                                                                                     HIV prevalence^a^, 34.9%
                                                                                                                                                                                                                                                                                             *Type-specific genotypes^b^*\                                                                                        HIV+, 59.5%\                                                                                                           
                                                                                                                                                                                                                                                                                             HPV 16/18, 18.4%\                                                                                                    HIV-, 39.1%\                                                                                                           
                                                                                                                                                                                                                                                                                             HPV 52, 14.2%\                                                                                                       *HR-HPV types^b^*\                                                                                                     
                                                                                                                                                                                                                                                                                             HPV 16, 7.5%\                                                                                                        HIV+, 100.0%\                                                                                                          
                                                                                                                                                                                                                                                                                             HPV 58, 7.5%                                                                                                         HIV-, 88.9%                                                                                                            

  *Young women below 25 years*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Banura et al., 2008a \[[@B16]\]     Clinic for teenagers in Kampala, 1275 sexually active young women median age 20 years (range 12-24)                                           Baseline of a cohort study                    SPF~10~/LIPA PCR assay                                     Any HPV^a^, 74.6%\                                                                                                   *HIV positive women*\                                                                                                  HIV prevalence^a^, 8.6%
                                                                                                                                                                                                                                                                                             HR-HPV types^a^, 51.4%\                                                                                              Any HPV^a^, 87.8%\                                                                                                     
                                                                                                                                                                                                                                                                                             *Type-specific genotypes^a^*\                                                                                        HR-HPV types, 67.1%\                                                                                                   
                                                                                                                                                                                                                                                                                             HPV 52, 13.2%\                                                                                                       *Type-specific genotypes^a^*\                                                                                          
                                                                                                                                                                                                                                                                                             HPV 51, 12.3%\                                                                                                       HPV 16, 18.3%\                                                                                                         
                                                                                                                                                                                                                                                                                             HPV 18, 10.7%\                                                                                                       HPV 18, 9.8%\                                                                                                          
                                                                                                                                                                                                                                                                                             HPV 16, 10.6%\                                                                                                       HPV 6, 15.9%\                                                                                                          
                                                                                                                                                                                                                                                                                             LR-HPV types^a^, 39.8%\                                                                                              HPV 11, 17.1%\                                                                                                         
                                                                                                                                                                                                                                                                                             *LR-HPV genotypes^a^*\                                                                                               *HIV negative women*\                                                                                                  
                                                                                                                                                                                                                                                                                             HPV 6, 15.5%\                                                                                                        Any HPV^a^, 73.2%\                                                                                                     
                                                                                                                                                                                                                                                                                             HPV 11, 13.3%                                                                                                        HR-HPV types^a^, 49.7%\                                                                                                
                                                                                                                                                                                                                                                                                                                                                                                                                  *Type-specific genotypes^a^*\                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                  HPV 16, 10.7%\                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                  HPV 18, 12.1%\                                                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                  HPV 6, 15.3%\                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                  HPV 11, 12.7%                                                                                                          

  Banura et al., 2008b \[[@B18]\]     Antenatal clinic in Kampala\                                                                                                                  Baseline of a cohort study                    SPF~10~/LIPA PCR assay                                     Any HPV^a^, 60.0%\                                                                                                   *HIV positive women*\                                                                                                  HIV prevalence^a^, 7.3%
                                      987 young primiparous pregnant women, median age 19 years (range 14-24)                                                                                                                                                                                High-risk types^b^, 43.0%\                                                                                           Any HPV^a^, 72.2%\                                                                                                     
                                                                                                                                                                                                                                                                                             *Type-specific genotypes^b^*\                                                                                        *Type-specific genotypes^b^*\                                                                                          
                                                                                                                                                                                                                                                                                             HPV 52, 12.1%\                                                                                                       HPV 16, 18.1%\                                                                                                         
                                                                                                                                                                                                                                                                                             HPV 51, 8.7%\                                                                                                        HPV 18, 6.9%\                                                                                                          
                                                                                                                                                                                                                                                                                             HPV 16, 8.4%\                                                                                                        HPV 6, 8.3%\                                                                                                           
                                                                                                                                                                                                                                                                                             HPV 18, 5.8%\                                                                                                        HPV 11, 1.4%\                                                                                                          
                                                                                                                                                                                                                                                                                             *LR-HPV genotypes*\                                                                                                  *HIV negative women*\                                                                                                  
                                                                                                                                                                                                                                                                                             LR-HPV types^b^, 23%\                                                                                                Any HPV^a^, 58.9%\                                                                                                     
                                                                                                                                                                                                                                                                                             *Type-specific genotypes^b^*\                                                                                        *Type-specific genotypes^b^*\                                                                                          
                                                                                                                                                                                                                                                                                             HPV 6, 5.5%\                                                                                                         HPV 16, 7.7%\                                                                                                          
                                                                                                                                                                                                                                                                                             HPV 11, 3.2%                                                                                                         HPV 18, 5.7%\                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                  HPV 6, 5.3%\                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                  HPV 11, 3.4%                                                                                                           

  **Screened adult women**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Buonaguro et al., 2000 \[[@B54]\]   Nsambya hospital, Scrapes of 16 women with normal ecto-cervical epithelium and different degrees of cervical epithelial lesions               Cross-sectional                               Southern Blot analysis                                     HPV 16^a^, 12.5%                                                                                                                                                                                                                            

  Taube et al., 2010 \[[@B19]\]       Post-natal clinic at Mulago hospital, Kampala\                                                                                                Cross-sectional                               Roche Linear array assay                                   Any HR-HPV^a^, 49.0%\                                                                                                *HIV positive*\                                                                                                        HIV prevalence^a^, 18.0%
                                      Cervical exfoliated cells from 196 women, 4-12 weeks post-partum and aged between 18-30 years (mean age for HIV -23 ± 3; HIV + 25.4 ± 3.2)                                                                                                             HPV 16/18^a^, 24%\                                                                                                   Any HR-HPV^a^, 77.8%\                                                                                                  
                                                                                                                                                                                                                                                                                             *HR-HPV types^a^*\                                                                                                   *Type-specific genotypes^a^*\                                                                                          
                                                                                                                                                                                                                                                                                             HPV 16, 8.2%\                                                                                                        HPV 16, 13.9%\                                                                                                         
                                                                                                                                                                                                                                                                                             HPV 18, 3.5%\                                                                                                        HPV 18, 5.6%\                                                                                                          
                                                                                                                                                                                                                                                                                             HPV 45, 5.1%\                                                                                                        HPV 45, 8.3%\                                                                                                          
                                                                                                                                                                                                                                                                                             HPV 58, 5.1%\                                                                                                        HPV 58, 5.6%\                                                                                                          
                                                                                                                                                                                                                                                                                             *LR-HPV types^a^*\                                                                                                   Other HR-HPV, 47.2%\                                                                                                   
                                                                                                                                                                                                                                                                                             HPV 6, 2.6%\                                                                                                         LR-HPV types\                                                                                                          
                                                                                                                                                                                                                                                                                             HPV 11, 1.0%                                                                                                         HPV 6, 5.6%\                                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                  HPV 11, 2.8%\                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                  *HIV negative*\                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                  Any HR-HPV^a^, 42.5%\                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                  *Type-specific genotypes^b^*\                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                  HPV 16, 6.9%\                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                  HPV 18, 3.1%\                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                  HPV 45, 4.4%\                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                  HPV 58, 5.0%\                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                  Other HR-HPV, 30.6%                                                                                                    
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*HR = High Risk; \*\*LR = Low Risk

^a^Denominator consist of all the tested women

^b^Denominator consist of only HPV positive women

###### 

HPV incidence in women without cervical abnormalities

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                              Area, subjects                                                                               Study design         HPV test                 HPV incidence rate for any, HR\*, LR\*\* and type-specific genotypes among all tested women^a^per 100 PYs   HPV incidence for any and type-specific genotypes all tested women^a^per 100 PYs by HIV status   Comments
  ----------------------------------- -------------------------------------------------------------------------------------------- -------------------- ------------------------ ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------ ----------------------------------------------
  Safaeian et al., 2008a \[[@B24]\]   Rakai district, rural women, median age 29 years (range, 15-59 years)                        Prospective cohort   HC 2/PGMY/09/11 assay    Any HR-HPV^a^, 8.7\                                                                                         *HIV Positive*\                                                                                  HIV prevalence^a^, 14.0%
                                                                                                                                                                                 *Type-specific genotypes^a^*\                                                                               Any HR-HPV^a^, 17.3\                                                                             
                                                                                                                                                                                 HPV 16, 1.5\                                                                                                *Type-specific genotypes^a^*\                                                                    
                                                                                                                                                                                 HPV 18, 0.9\                                                                                                HPV 16, 3.2\                                                                                     
                                                                                                                                                                                 HPV 45, 1.1\                                                                                                HPV 18, 2.1\                                                                                     
                                                                                                                                                                                 HPV 51, 1.8\                                                                                                HPV 45, 2.7\                                                                                     
                                                                                                                                                                                 HPV 52, 1.1                                                                                                 HPV 51, 5.1\                                                                                     
                                                                                                                                                                                                                                                                                             HPV 52, 1.3\                                                                                     
                                                                                                                                                                                                                                                                                             *HIV Negative*\                                                                                  
                                                                                                                                                                                                                                                                                             Any HR-HPV^a^, 7.0\                                                                              
                                                                                                                                                                                                                                                                                             *Type-specific genotypes*^a^\                                                                    
                                                                                                                                                                                                                                                                                             HPV 16, 1.2\                                                                                     
                                                                                                                                                                                                                                                                                             HPV 18, 0.7\                                                                                     
                                                                                                                                                                                                                                                                                             HPV 45, 0.8\                                                                                     
                                                                                                                                                                                                                                                                                             HPV 51, 1.2\                                                                                     
                                                                                                                                                                                                                                                                                             HPV 52, 1.0                                                                                      

  Banura et al., 2010 \[[@B25]\]      Teenage clinic in Kampala, 380 young women, median age at baseline 19 years (range, 12-24)   Prospective cohort   SPF~10~/LIPA PCR assay   Any HPV^a^, 30.5\                                                                                           *HIV Positive*\                                                                                  *Cumulative prevalence over 27.5 months^a^*\
                                                                                                                                                                                 HR-HPV types, 20.9\                                                                                         Any HR-HPV^a^, 40.0\                                                                             HR-HPV types, 68.2%\
                                                                                                                                                                                 LR-HPV types, 10.6\                                                                                         *Type-specific genotypes^a^*\                                                                    LR-HPV types, 55.0%\
                                                                                                                                                                                 HPV 16-related types, 10.8\                                                                                 HPV 16, 6.7\                                                                                     HPV 16-related types, 48.6%\
                                                                                                                                                                                 HPV 18-related types, 5.6\                                                                                  HPV 18, 3.0\                                                                                     HPV 18-related types, 28.2%
                                                                                                                                                                                 *Type-specific genotypes*\                                                                                  *HIV Negative*\                                                                                  
                                                                                                                                                                                 *HR-HPV genotypes^a^*\                                                                                      Any HR-HPV^a^, 29.7\                                                                             
                                                                                                                                                                                 HPV 16, 3.3\                                                                                                *Type-specific genotypes^a^*\                                                                    
                                                                                                                                                                                 HPV 18, 2.0\                                                                                                HPV 16, 3.0\                                                                                     
                                                                                                                                                                                 HPV 45, 1.3\                                                                                                HPV 18, 2.1                                                                                      
                                                                                                                                                                                 HPV 51, 4.2\                                                                                                                                                                                                 
                                                                                                                                                                                 HPV 52, 3.4\                                                                                                                                                                                                 
                                                                                                                                                                                 *LR-HPV genotypes^a^*\                                                                                                                                                                                       
                                                                                                                                                                                 HPV 6, 3.4\                                                                                                                                                                                                  
                                                                                                                                                                                 HPV 11, 1.9                                                                                                                                                                                                  
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HR\* = High Risk

LR\*\* = Low Risk

^a^Denominator consist of all the tested women

PYs = Person Years

###### 

HPV prevalence and genotype distribution among invasive cervical cancer cases

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                            Area, subjects                                                                                                                                  Study design   HPV test                 HPV prevalence for any and specific genotypes among all tested women^a^   Comments
  --------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------- -------------- ------------------------ ------------------------------------------------------------------------- -------------------------------------------------
  Schmauz et al., 1989 \[[@B55]\]   Mulago hospital, cervical tissues from 34 cases and 23 controls                                                                                 Case Control   Southern Blot analysis   Cases^a^\                                                                 *Prevalence of HIV*^a^\
                                                                                                                                                                                                                            HPV 16/18, 50%\                                                           Cases, 5.9%\
                                                                                                                                                                                                                            HPV 16, 15%\                                                              Controls, 21.7%\
                                                                                                                                                                                                                            HPV 18, 35%\                                                              *Odds of cervical cancer*\
                                                                                                                                                                                                                            Controls^a^\                                                              HPV 18 (OR\* = 12.0)\
                                                                                                                                                                                                                            HPV 18, 4.4%                                                              HPV16/18 (OR\* = 22.0)

  Odida et al., 2008 \[[@B56]\]     Mulago, Pathology Department 186 paraffin embedded histologically confirmed archival cervical cancer cases\                                     Case series    SPF~10~/LIPA             Any HPV^a^, 61.3%\                                                        Types\
                                    Collected 1968-69, 1970-79, and 1980-89.                                                                                                                                                *Type-specific genotypes*^a^\                                             146 Squamous cell carcinoma\
                                                                                                                                                                                                                            HPV 16/18, 73.5%\                                                         35 adenocarcinoma\
                                                                                                                                                                                                                            HPV 16, 44.7%\                                                            3 Adenosquamous\
                                                                                                                                                                                                                            HPV 18, 28.8%\                                                            2 undifferentiated types
                                                                                                                                                                                                                            HPV 45, 9.6%                                                              

  Odida et al., 2010 \[[@B57]\]     Mulago Hospital, Kampala, 171 pairs of paraffin embedded and freshly frozen tissue samples collected between September 2004 and December 2006   Case series    SPF~10~/LIPA             Any HPV^a^, Frozen tissue, 90.1%\                                         Multiple HPV genotypes^a^\
                                                                                                                                                                                                                            *Type-specific genotypes*^a^\                                             Frozen tissue, 7.1%\
                                                                                                                                                                                                                            HPV 16, 47.4%\                                                            Paraffin embedded, 4.6%\
                                                                                                                                                                                                                            HPV 18, 19.5%\                                                            Single HPV genotypes^a^\
                                                                                                                                                                                                                            HPV 45, 9.7%\                                                             Frozen tissue, 92.9% (95% CI^†^: 87.6-96.4)\
                                                                                                                                                                                                                            HPV 51, 1.9%\                                                             Paraffin embedded, 94.7% (95% CI^†^: 89.9-97.7)
                                                                                                                                                                                                                            HPV 52, 1.3%\                                                             
                                                                                                                                                                                                                            Any HPV^a^, Paraffin embedded tissue, 88.9%\                              
                                                                                                                                                                                                                            *Type-specific genotypes*^a^\                                             
                                                                                                                                                                                                                            HPV 16, 47.4%\                                                            
                                                                                                                                                                                                                            HPV 18, 23.7%\                                                            
                                                                                                                                                                                                                            HPV 45, 7.9%\                                                             
                                                                                                                                                                                                                            HPV 51, 1.3%\                                                             
                                                                                                                                                                                                                            HPV 52, 1.3%                                                              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Denominator consist of all the tested women

CI^†^= Confidence Interval

OR\* = Odds Ratio

###### 

HPV prevalence in males participating in circumcision clinical trials

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                             Area, subjects                                                                                                                                                    Study design                  HPV test                                                                                                    HPV prevalence for HR\*, and LR\*\* genotypes at enrollment and 24 month follow up in intervention§ and control§§   HPV prevalence for any, HR\* and LR\*\* genotypes at baseline and 24-month follow-up   Risk Ratio (RR) and 95% CI† for any, HR\*, LR\*\* and multiple HPV infections at baseline and 24-month follow-up
  ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------- ----------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------
  Tobian et al., 2009 \[[@B58]\]     Rakai district, 307 men in intervention and 233 men in control group aged 15-49 years who had detectable beta-globulin or HPV. Preputal cavity sampled            Randomized controlled trial   Roche HPV linear array. HR-HPV genotypes 16, 18,31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 tested   At enrollment\                                                                                                      Intervention\                                                                          Any HPV genotypes^b^\
                                                                                                                                                                                                                                                                                                                                                 *HR-HPV genotypes*^a^\                                                                                              Any HPV genotype^b^\                                                                   Baseline, 0.99 (0.81-1.21)\
                                                                                                                                                                                                                                                                                                                                                 Intervention group, 38.1%\                                                                                          Baseline, 61.9%\                                                                       At 24 months, 0.70 (0.53-0.91)\
                                                                                                                                                                                                                                                                                                                                                 Control group, 37.1%\                                                                                               At 24 months, 35.6%\                                                                   *HR-HPV genotypes*^b^\
                                                                                                                                                                                                                                                                                                                                                 At 24 months\                                                                                                       *HR-HPV genotypes*^b^\                                                                 Baseline, 1.03 (0.79-1.33)\
                                                                                                                                                                                                                                                                                                                                                 *HR-HPV genotypes*^a^\                                                                                              Baseline, 38.1%\                                                                       At 24 months, 0.65 (0.45-0.94)\
                                                                                                                                                                                                                                                                                                                                                 Intervention group, 18.0%\                                                                                          At 24 months, 18.0%\                                                                   *LR-HPV genotypes*^b^\
                                                                                                                                                                                                                                                                                                                                                 Control group, 27.9%                                                                                                *LR-HPV genotypes*^b^\                                                                 Baseline, 0.99 (0.79-1.25)\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Baseline, 47.6%\                                                                       At 24 months, 0.66 (0.49-0.91)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     At 24 months, 26.2%\                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Control group\                                                                         
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Any HPV types^b^\                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Baseline, 62.6%\                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     At 24 months, 51.2%\                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     *HR-HPV genotypes*^b^\                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Baseline, 37.1%\                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     At 24 months, 27.9%\                                                                   
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     *LR-HPV genotypes*^b^\                                                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Baseline, 48.0%\                                                                       
                                                                                                                                                                                                                                                                                                                                                                                                                                                                     At 24 months, 39.4%                                                                    

  Serwadda et al., 2010 \[[@B59]\]   Rakai district, uncircumcised HIV positive men aged 15-49 years; 103 men in intervention group and 107 men in control group                                       Randomized controlled trial   Roche HPV linear array                                                                                      At enrollment\                                                                                                                                                                                             At 24 months\
                                                                                                                                                                                                                                                                                                                                                 *HR-HPV genotypes*^a^\                                                                                                                                                                                     *RR for HR-HPV geno*types 0.77 (0.62-0.97)\
                                                                                                                                                                                                                                                                                                                                                 Intervention group, 72.2%\                                                                                                                                                                                 *RR for multiple genotypes*0.53 (0.33-0.83)
                                                                                                                                                                                                                                                                                                                                                 Control group, 76.6%\                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                 *LR-HPV genotypes*^a^\                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                 Intervention group, 85.6%\                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                 Control group, 83.0%\                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                 At 24 months\                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                 *HR-HPV genotypes*^a^\                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                 Intervention; 55.3%\                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                 Control group; 71.7%\                                                                                                                                                                                      
                                                                                                                                                                                                                                                                                                                                                 *LR-HPV genotypes*^a^\                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                 Intervention group, 49.4%\                                                                                                                                                                                 
                                                                                                                                                                                                                                                                                                                                                 Control group, 77.4%                                                                                                                                                                                       

  Gray et al., 2010 \[[@B60]\]       Rakai district, uncircumcised HIV negative men aged 15-49 years; 441 randomized to immediate circumcision (intervention) and 399 delayed circumcision (control)   Randomized controlled trial   Roche HPV linear array                                                                                      *At enrollment*\                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                 *HR-HPV genotypes*^a^\                                                                                                                                                                                     
                                                                                                                                                                                                                                                                                                                                                 Intervention arm, 39.1%\                                                                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                 Control arm, 38.6%                                                                                                                                                                                         
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HR\* = High Risk

LR\*\* = Low Risk

CI^†^= Confidence Intervals

^a^Denominator include all women tested

^b^Denominator include only HPV positive women

^§^Intervention refers to circumcision arm of the study

^§§^Control refers to non circumcision arm of the study

###### 

HPV incidence in males participating in circumcision clinical trials

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                             Area, subjects                                                                                                                Study design                  HPV test                 HPV incident cases^c^and rates^d^for type-specific genotypes per 100 PYs   Proportions of type-specific incident infections at 24-month follow-up   Risk Ratio (RR) and 95% CI^†^for HR\* and multiple infections                                                                           
  ---------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ----------------------------- ------------------------ -------------------------------------------------------------------------- ------------------------------------------------------------------------ --------------------------------------------------------------- --------- ----------------------------------------------- ------------- --
  Serwadda et al., 2010 \[[@B59]\]   Rakai district, uncircumcised HIV positive men aged 15-49 years; 103 men in intervention group and 107 men in control group   Randomized controlled trial   Roche HPV linear array   At 24 months\                                                              Incident proportions                                                     At 24 months\                                                                                                                           
                                                                                                                                                                                                                          HR-HPV incident cases^c^\                                                                                                                           RR for HR-HPV types = 0.74 (0.54-1.01)\                                                                                                 
                                                                                                                                                                                                                          Intervention group, 42 cases\                                                                                                                       RR for multiple infection = 0.04 (0.19-0.84).                                                                                           
                                                                                                                                                                                                                          Control group, 57 cases\                                                                                                                                                                                                                                                                    
                                                                                                                                                                                                                          *Multiple infectionincident cases*^c^\                                                                                                                                                                                                                                                      
                                                                                                                                                                                                                          Intervention group, 9.9 cases\                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                          Control group, 24.7 cases                                                                                                                                                                                                                                                                   

                                                                                                                                                                                                                                                                                                                                                                                                                                                        Intervention^d^\                                Control^d^\   
                                                                                                                                                                                                                                                                                                                                                                                                                                                        (%)                                             (%)           

                                                                                                                                                                                                                                                                                                                                                                                                                                              HPV 16\   5.8\                                            14.9\         
                                                                                                                                                                                                                                                                                                                                                                                                                                              HPV 18\   4.3\                                            11.1\         
                                                                                                                                                                                                                                                                                                                                                                                                                                              HPV 45\   4.1\                                            10.3\         
                                                                                                                                                                                                                                                                                                                                                                                                                                              HPV 51\   5.4\                                            13.9\         
                                                                                                                                                                                                                                                                                                                                                                                                                                              HPV 52    10.1                                            8.2           

  Gray, et al. 2010 \[[@B60]\]       Rakai district, uncircumcised HIV negative men aged 15-49 years; 441 men in intervention and 399 men in control group         Randomized controlled trial   Roche HPV linear array   At 24 months\                                                                                                                                                                                                                 At 24 months\                                                 
                                                                                                                                                                                                                          *HR-HPV incident cases*^c^\                                                                                                                                                                                                   RR for HR-HPV types = 0.67 (0.51-0.89)\                       
                                                                                                                                                                                                                          Intervention group, 19.7 cases\                                                                                                                                                                                               RR for multiple infections = 0.45 (0.28-0.73)                 
                                                                                                                                                                                                                          Control group, 29.4 cases\                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                          *Multiple infection incident cases^c^*\                                                                                                                                                                                                                                                     
                                                                                                                                                                                                                          Intervention group, 6.7 cases\                                                                                                                                                                                                                                                              
                                                                                                                                                                                                                          Control group, 14.8 cases\                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                          *Type specific incidence rates^d^*                                                                                                                                                                                                                                                          

                                                                                                                                                                                                                                                                                                     Intervention                                                             Control                                                                                                                                 

                                                                                                                                                                                                                                                                                                     Incidence/100 PYs                                                                                                                                                                                                

                                                                                                                                                                                                                          HPV 16\                                                                    3.6\                                                                     4.8\                                                                                                                                    
                                                                                                                                                                                                                          HPV 18\                                                                    1.6\                                                                     5.3\                                                                                                                                    
                                                                                                                                                                                                                          HPV 45\                                                                    1.6\                                                                     2.4\                                                                                                                                    
                                                                                                                                                                                                                          HPV 51\                                                                    4.0\                                                                     5.3\                                                                                                                                    
                                                                                                                                                                                                                          HPV 52                                                                     1.6                                                                      3.6                                                                                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HR\* = High Risk

CI^†^= Confidence Intervals

PYs = Person Years

^c^Denominator include all women tested

^d^Denominator include women with HR-HPV

###### 

HPV Seroprevalence among women with and without invasive cervical cancer

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                             Area, subjects                                                                                                                                                               Study design      HPV test                                       HPV seroprevalence for any and type specific genotypes   HPV seroprevalence of any and type specific genotypes among HIV positive women   Comments
  ---------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------- ---------------------------------------------- -------------------------------------------------------- -------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------
  Newton, et al., 2004) \[[@B27]\]   Mulago hospital, 191 cervical cancer cases and 336 controls; 15 years and older with a new diagnosis of cancer from the wards or outpatient clinics between 1994 and 1998.   Case Control      HPV L1 VLP/ELISA                               *Cases*\                                                 *HIV Positive Controls*\                                                         Antibodies against HPV 16 were significantly associated with cervical cancer OR\* = 2.0 (1.2-3.1)\
                                                                                                                                                                                                                                                                                   *Type-specific genotypes*^*a*^\                          Any of 3 HPV types^a^, 22% *Type-specific genotypes^a^*\                         The risk increased with increasing anti-HPV 16 antibody titre (P~trend~= 0.01)
                                                                                                                                                                                                                                                                                   HPV 16, 27%\                                             HPV 16, 16%\                                                                     
                                                                                                                                                                                                                                                                                   HPV 18, 7%\                                              HPV18, 7%\                                                                       
                                                                                                                                                                                                                                                                                   HPV 45, 9%\                                              HPV 45, 8%                                                                       
                                                                                                                                                                                                                                                                                   *Controls*\                                                                                                                               
                                                                                                                                                                                                                                                                                   Any of 3 HPV types^a^, 17%\                                                                                                               
                                                                                                                                                                                                                                                                                   *Type-specific genotypes*^*a*^\                                                                                                           
                                                                                                                                                                                                                                                                                   HPV 16, 11%\                                                                                                                              
                                                                                                                                                                                                                                                                                   HPV 18, 5%\                                                                                                                               
                                                                                                                                                                                                                                                                                   HPV 45, 6%                                                                                                                                

  Namujju, et al., 2010 \[[@B26]\]   Naguru and Nsambya Health Centers in Kampala, 2,053 women seeking antenatal services; mean age 23 years (range, 14-48)                                                       Cross-sectional   Serology/VLP ELISA (6, 11, 16,18,31, 33, 45)   Any of the 7 selected HPV types^a^, 57%                                                                                                   HIV prevalence^a^, 7.0%
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^Denominator consist of all tested women

OR\* = Odds Ratio

Prevalence of HPV infections in population-and clinic-based studies of women with and without cervical abnormalities
--------------------------------------------------------------------------------------------------------------------

In women below 25 years, 71.8% of women who were positive for HPV 16 and 18 were also infected with other HR-HPV genotypes \[[@B16]\]. Compared to HIV negative women, HIV positive women had more HR-HPV genotypes detected in cervical/vaginal specimens \[[@B16]-[@B19]\] and HSIL lesions \[[@B17]\]. The mean number of HPV genotypes detected was higher among HIV positive compared to HIV negative women (2.8; range 1-9) and 2.1; range 1-10, respectively; \[*t*-test, 3.88; p \< 0.001\]) \[[@B16]\]. Likewise, among young primiparous women, the mean number of HPV types detected among HIV positive women was higher (2.4, range 1-10) than among HIV negative women (1.8, range 1-12) \[Student\'s t-test = 2.79, p = 0.005\] \[[@B18]\]. HIV positive women were four times more likely to have abnormal cytology than HIV negative women (43% vs. 11.6%, p \< 0.001) \[[@B19]\]. HPV positive women co-infected with HIV had other HR-HPV genotypes that did not include HPV 16 or 18 \[[@B16],[@B17]\].

Risk factors for prevalent HPV infection
----------------------------------------

Few studies evaluated risk factors for HPV infections. Lifetime number of sexual partners \[[@B16],[@B20]\]; HIV positivity \[[@B16],[@B21]\]; young age at first sexual intercourse \[[@B16]\] and young age \[[@B16],[@B21]\] were significantly associated with HPV infection. Relative to women in 19-25 age-group, the odds of detecting HR-HPV decreased by 48%, 60%, and 79% among women in 26-30, 31-37, and 38-49 age-group \[[@B21]\]. On average, the odds of detecting HR-HPV decreased by 9% for each-year increase in age. However, HPV was only inversely associated with age (P~trend~0.001) in HIV negative women as the prevalence of HPV among HIV positive women seemed to remain high in all age-groups \[[@B20]\]. Other risk factors found included: abnormal cytology \[[@B17],[@B18]\]; employment in a tertiary sector, concurrent pregnancy, presence of genital warts, and testing positive for *Syphilis, Chlamydia trachomatis*and *Neisseria Gonnorhea*\[[@B16]\]. Smoking cigarettes the previous year was significantly associated with HPV infection after controlling for age, age at sexual debut and HIV status (Adjusted OR = 3.74; 95% CI: 1.15-12.16) \[[@B21]\].

HPV 16 and 18 were the most frequent genotypes in ICC cases. Furthermore, results of pooled data compiled by the International Agency for Research on Cancer (IARC) showed a prevalence of HPV 16/18 of 74.1% (95% CI: 66.4-80.8) \[[@B22],[@B23]\].

Incident and risk factors for HPV infections among women
--------------------------------------------------------

HIV positive women were twice as likely to have incident infection compared to HIV negative women \[[@B24]\]. Risk factors for incident HPV infections were HIV positivity \[[@B24],[@B25]\]; young age, many lifetime and recent sexual partners and single women \[[@B24],[@B25]\].

Risk factor for HPV infection in males participating in circumcision trials
---------------------------------------------------------------------------

Not being circumcised was the main risk factor for both prevalence and incident HR-HPV infections.

HPV serology
------------

HPV seroprevalence peaked in women below 20 years of age. The most common HR-HPV serotypes was HPV 33 (23%), HPV 16 (21%), HPV 31 (16%), HPV 45 (11%) and HPV 18 (8%). The seroprevalence of LR-HPV 6, 11 and HPV 6/11 combined was 30%, 26%, and 44%, respectively. Of the 1,118 HPV seropositive women, 53% had antibodies to more than one HPV genotype, 30% had 2 HPV genotypes, 14% had 3 HPV genotypes and 9% had 4-7 genotypes \[[@B26]\]. Antibodies against HPV 16 were significantly associated with ICC (OR = 2.0; 95% CI: 1.2-3.1, p \< 0.01) \[[@B27]\]. HPV seoprevalence was higher among HIV positive compared to HIV negative women, 74.0% and 56%, respectively. Multiple antibody positivity was more frequent in HIV positive (53%) than HIV negative women (28%) \[[@B26]\].

Discussion
==========

To the best of our knowledge, this systematic review represents the first ever to evaluate the burden of HPV infections and ICC in Uganda. It is worth noting that comparison of HPV prevalence and incidence rates across studies was hampered by differences in populations studied, laboratory methods used, and variation in HPV genotypes detected. Nevertheless, consistent with other studies in sub Saharan Africa \[[@B28]\], the review demonstrated a high burden of HR-HPV genotypes in the general population and in ICC. HPV 16 and 18 were the most common genotypes in ICC similar to the global HPV distribution pattern \[[@B29]\]. Mathematical models predict that widespread use of preventive HPV vaccines containing genotypes 16/18 have the potential to reduce deaths from ICC by 50% over several decades \[[@B30]-[@B32]\]. However, the efficacy of these vaccines in countries like Uganda with high prevalence of HIV infection, endemic malnutrition, malaria infection and intestinal worm infestation is not yet known. Our review also found that the third most frequent HPV genotype after HPV 16 and 18 among women with ICC was HPV 45, which differed from the worldwide distribution (HPV 16, 18, 58) \[[@B9]\]. Variation in HPV genotype distribution in ICC is not new as it has been observed in other regions of the world. It is hypothesized that host immunogenetic factors and biologic interplay between different HPV genotypes or variants are probably responsible \[[@B32]\]. This variation however, implies that any development of the next generation of multivalent preventive HPV vaccines should contain more HR-HPV genotypes than only 16/18. Based on data contained in this review, multivalent vaccines containing HPV 16/18/45 would potentially prevent approximately 83.1% of ICC in Uganda.

The highest prevalence and incidence rates of HPV infections occurred in young women below 25 years similar to previous studies \[[@B23]\]. It is important to note that Ugandan women tend to marry and become sexually active at a young age and often have older and more sexually experienced partners, which factors would put them at greater risk for HPV infection. The main risk factors for prevalent and incident HPV infections were age, number of lifetime number of sexual partners and HIV infection consistent with other studies \[[@B23],[@B33]\].

HIV positive individuals had a high burden of HPV infection at the time when their life-spans are being prolonged by expanded access to highly active anti-retroviral therapy (HAART) and medical care. Since 2003, the HIV prevalence in Uganda has stabilized at about 6.4% among adults and by the end of 2010; approximately 1.1 million were living with HIV \[[@B34]\]. Women were disproportionately affected accounting for about 57% of the total adults living with HIV \[[@B34]\]. However, the proportion of co-infection with HIV and HPV is not known. Though several studies have consistently shown a high burden of HPV-associated diseases in HIV positive women even in the era of HAART \[[@B35]\], presently, there is limited or noexistent routine screening services for many HIV positive women. There are advantages to providing routine screening to HIV positive women. In Zambia, for example, routine screening prevented one death from ICC for every 46 HIV positive women screened \[[@B36]\]. Presently, there is limited data to support or discourage HPV vaccination of HIV positive individuals. To date, immune response to HPV vaccination among HIV positive individuals using the quadrivalent vaccine is limited to a small study of 120 children aged 7-11 years some of whom used anti retroviral therapy, which was conducted in the USA \[[@B37]\]. The antibodies developed by \> 99.5% of the vaccinated children were much lower than in HIV negative historical controls raising concerns of perhaps reduced immunogenicity and efficacy.

In this review, HIV positive women seemed to have multiple and more other HR-HPV genotypes than HPV 16/18 consistent with a previous study where 50% of HIV positive women with HPV 16 and 18 were co-infected with other HR-HPV genotypes \[[@B38]\]. Consequently, it is unclear whether the current vaccines containing only HPV 16 and 18 genotypes may potentially prevent fewer cases of ICC among HIV positive women \[[@B39]\]. Fortunately, the current preventive vaccines have shown cross-protection against some non vaccine HR-HPV genotypes and because of this, it is estimated that wide coverage (\> 70%) could potentially prevent up to 71% of ICC \[[@B40]\]. Cross-protection even if limited, may be particularly important in low-resource countries like Uganda where screening programs are limited or nonexistent.

Males had a high burden of HR-HPV infections. Studies have shown that males do not perceive themselves to be susceptible to HPV and do not believe that HPV infection is a severe problem to themselves \[[@B41]\]. However, the role of men as vectors of HR-HPV genotypes that cause ICC has been extensively evaluated in epidemiological studies \[[@B42]-[@B44]\]. HPV vaccines have been found to be safe and efficacious in males \[[@B45]\]. However, vaccinating males does not appear to be economical when assessed from the view of ICC. Moreover, the WHO does not recommend routine male vaccination as the primary target of vaccination. Yet, the concept of herd immunity in public health would tend to suggest that vaccinating males would provide a double benefit to females in that the fewer males with HPV, the fewer females will be exposed \[[@B46]\].

Although HPV vaccines hold great promise to reduce ICC-associated mortality and morbidity, it remains unclear whether low-resource countries like Uganda will reap the benefits any time soon. The current high cost of the vaccines, poor health infrastructure and competing health priorities will prevent young girls getting the life saving vaccinations. Uganda\'s health sector remains considerably under-funded. At less than 10% of total government expenditure in fiscal year 2010/2011, public health expenditure remains far below the Abuja target of 15% that the government of Uganda committed to in 2001 \[[@B47],[@B48]\]. Furthermore, presently, there is no known public sector pricing for the HPV vaccines making it difficult to budget for and as such the details of vaccine implementation and cost coverage remain unknown. Fortunately, the Global Alliance for Vaccines and Immunization (GAVI) pledged to consider HPV vaccines in their investment strategy of 2009-2013 \[[@B49]\]. This may provide the much needed financial help to implement HPV immunization programs in low-resource countries where most of the ICC occur.

For prevention, HPV vaccines must be given before sexual debut to ensure that exposure to HPV has not occurred. Accordingly, the World Health Organization recommended that girls between the ages of 9-13 years should be the primary target of vaccination \[[@B50]\]. Given the financial impossibility of vaccinating all eligible women in the reproductive age, it is vital that primary prevention by HPV vaccination is integrated with education on risk reducing behaviors and secondary prevention programs via screening and treatment of precancerous lesions and ICC. The availability of new and inexpensive screening techniques for rapid identification of HR-HPV may help facilitate the use of HPV testing in low-resource countries \[[@B51]\].

Conclusions
===========

HR-HPV infections were frequent in both females and males. HR-HPV 16 and 18 targeted by the two licensed preventive HPV vaccines are the most common genotypes found in ICC cases. However, there are a large number of individuals infected with other non vaccine HR-HPV genotypes not targeted by the currently available HPV vaccine preparations, indicating that these vaccines could be less effective and leave women at risk for ICC. Furthermore, given the high prevalence of HIV infection, HPV-associated conditions represent a major public health burden in Uganda. Thus, to further reduce this health burden, any future preventive HPV vaccine(s) should contain more HR-HPV genotypes than only two targeted by the current vaccines.
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